2024-11-23 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Relative to S&P 500 (VOO):**

Johnson & Johnson (JNJ) is a diversified healthcare company that manufactures medical devices, pharmaceuticals, and consumer goods.

The cumulative return of JNJ is 36.03%, while the S&P 500 (VOO) has a cumulative return of 127.58%.  This represents a significant underperformance of JNJ compared to the market benchmark. The difference in cumulative returns is -91.55%. The relative divergence, considering historical volatility, places JNJ at the 2.45th percentile, indicating it has significantly underperformed the S&P 500 over the period considered.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|------|
| 2015-2017  | 45.2% | 9.0% | 6.8% | 0.7 | 336.4 |
| 2016-2018  | 39.2% | 16.9% | 6.9% | 0.7 | 310.7 |
| 2017-2019  | 36.4% | 16.9% | -15.3% | 0.7 | 351.2 |
| 2018-2020  | 22.6% | 26.5% | -24.7% | 0.7 | 378.9 |
| 2019-2021  | 45.0% | 26.5% | -55.0% | 0.6 | 411.9 |
| 2020-2022  | 30.8% | 26.5% | 7.2% | 0.5 | 425.3 |
| 2021-2023  | 8.6% | 14.6% | -26.4% | 0.3 | 377.4 |
| 2022-2024  | -2.1% | 14.6% | -32.2% | 0.2 | 374.4 |

**Analysis of Alpha and Beta:** JNJ consistently shows a beta less than 1, indicating lower volatility than the overall market. However, the alpha is mixed, suggesting periods of both outperformance and underperformance relative to the market.  The declining CAGR over the recent years is a significant concern.


**2. Recent Price Movement:**

* Last Closing Price: $155.15
* 5-Day Moving Average: $154.31
* 20-Day Moving Average: $156.36
* 60-Day Moving Average: $161.14

The price is currently below its 20-day and 60-day moving averages, suggesting a downward trend.


**3. Technical Indicators and Expected Return:**

* RSI: 39.91 (Approaching oversold territory, but not definitively so)
* PPO: 0.05 (Slightly positive, suggesting a potential bullish momentum but weak)
* 20-Day Relative Divergence Change: -3.73 (Short-term bearish)
* Expected Return (2+ years): 0.0% (This indicates that, based on the provided data, no significant outperformance relative to the S&P 500 is expected over the long term)


**4. Recent Financial Performance:**

| Date       | EPS     | Revenue      |
|------------|---------|--------------|
| 2024-10-23 | 1.12    | $22.47 B     |
| 2024-07-25 | 1.95    | $22.45 B     |
| 2024-05-01 | 1.35    | $21.38 B     |
| 2024-02-16 | 1.68    | $21.39 B     |
| 2023-10-27 | 10.32   | $21.35 B     |

**Analysis:**  EPS shows significant variability quarter-to-quarter. The October 2023 EPS is unusually high compared to other quarters, needing further investigation to determine if this is an anomaly or reflects a change in reporting practices. Revenue has remained relatively consistent.  Further analysis including analyst estimates for the most recent quarter is necessary for a comprehensive assessment.

**6. Financial Information:**

**1) Revenue and Profitability:**

| Quarter     | Revenue    | Profit Margin |
|-------------|------------|---------------|
| 2024-09-30  | $22.47B    | 69.01%        |
| 2024-06-30  | $22.45B    | 69.40%        |
| 2024-03-31  | $21.38B    | 69.55%        |
| 2023-12-31  | $21.39B    | 68.23%        |
| 2023-09-30  | $21.35B    | 69.06%        |

**Analysis:** Profit margins are consistently high, demonstrating strong profitability. Revenue is relatively stable.


**2) Capital and Profitability:**

| Quarter     | Equity     | ROE      |
|-------------|------------|----------|
| 2024-09-30  | $70.16B    | 3.84%    |
| 2024-06-30  | $71.54B    | 6.55%    |
| 2024-03-31  | $70.02B    | 4.65%    |
| 2023-12-31  | $68.77B    | 5.89%    |
| 2023-09-30  | $71.23B    | 36.54%   |

**Analysis:**  The September 2023 ROE is exceptionally high and needs further investigation. Equity shows relatively stable trends, with some minor fluctuations.


**7. News and Recent Issues:**

*(This section requires access to real-time news sources such as Shacknews and Finbold.  I cannot provide specific news items without access to those sources.  Please provide the relevant news articles for a complete analysis.)*  A search for recent JNJ earnings news and analyst opinions should be conducted to understand recent market sentiment and potential catalysts for future price movement.

**8. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 over the analyzed period. While the company demonstrates strong profitability and consistent revenue, recent EPS volatility and the substantial underperformance relative to the market raise concerns. Technical indicators suggest a potential bearish trend in the short term, though the RSI is not definitively oversold. The lack of expected outperformance against the S&P 500 underscores the need for cautious optimism.  A thorough review of recent news, including earnings calls and analyst reports, is crucial to making an informed investment decision.  The extremely high ROE in September 2023 requires investigation to understand its cause.

**9. Disclaimer:** This analysis is based on the limited data provided and should not be considered financial advice.  Conduct thorough independent research and consult with a financial advisor before making any investment decisions.
